STERIS plc

STERIS plc (STE) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Moat durability: Switching costs are brutal. Re‑validating a sterilizer takes months, costs millions. Once a hospital installs STERIS equipment, it buys the consumables and service contracts for decades. Regulatory compliance is a permanent tailwind – no sterilization, no surgery.
• Recurring revenue engine: >55% of Healthcare revenue comes from consumables + service – the razor‑blade model. $0.8B FCF in FY2025, consistently above net income. Cash flow is honest and growing (FCF CAGR 15.2%).
• Pricing power: Consumables + service grew 6–8% organically in FY2025. Hospitals didn’t flinch at price increases. Operating margins in Healthcare (25%) and AST (24%) confirm it.
• Balance sheet cleanup: Debt slashed from $3.1B (2024) to $1.9B (2025). D/E now 0.29x. Management is repairing, not destroying.
• What makes it exceptional? Not ROE (9.3% is mediocre). Not growth (GDP‑like organic). Exceptional is the stickiness. This is a toll road – you pay to keep your OR open. At the right price, it’s a steady compounder.

Honest caveat: This is not a 20% ROE business. It’s a 10–12% ROE business that throws off reliable cash. Berkshire can own that if the price is cheap enough.

🐻 The Bear Case (Charlie inverts)

• Single‑use disposables (the kill shot): If hospitals pivot entirely to disposable instruments, STERIS’s core equipment and service business shrinks. But regulatory validation for disposables is also expensive. Unlikely in 10 years. Not impossible – the trend is toward convenience, and disposables eliminate sterilization risk.
• Goodwill time bomb: $1.9B of goodwill on Healthcare segment alone. Another bad acquisition (Cantel 2.0) or a sudden shift to disposables could trigger impairment. Earnings volatility is baked in – FY2023 net income was $0.1B on $5.1B revenue. That’s a 2% margin. The moat survived, but shareholder trust didn’t.
• Management’s capital allocation record: Overpaid for Cantel. Earnings collapsed immediately. ROE hit 1.8% in 2023. They fixed it, but they broke it first. The next deal will test if they learned. If they lever up again, the same risk returns.

Most likely structural threat: Single‑use disposables penetrating high‑volume, low‑complexity procedures (e.g., basic surgical kits). Over 15–20 years, this could shrink the addressable market for re‑sterilization. Not imminent, but real.

💰 Valuation & Margin of Safety

• DCF intrinsic value estimate: $283.53 per share (15% FCF growth, 10% discount, 3% terminal). This assumes the recovery holds and FCF compounds. But the 2022–2023 profit collapse shows the path is lumpy.
• 25% margin of safety entry: $212.65 (conservative – assumes some execution risk).
• 50% margin of safety entry: $141.77 (Buffett’s ideal – only if you want to ignore management risk entirely).
• Current price context: At ~$230 (recent range), it’s 15% below intrinsic but only 7% above conservative entry. Not cheap enough for a business with mediocre ROE and a history of self‑inflicted wounds.

Verdict: WATCH

At $230, STERIS offers a decent but not compelling entry – the moat is real, but management has not earned the trust required for a 20‑year hold without a wider safety margin. If the price drops to $210 or below, the 25% margin of safety triggers a serious look – but for now, let the cash pile grow and wait for either a better price or a clear signal that management will avoid big acquisitions. This is a fine business, not a great one, and the price must reflect that.